[Use of Spectinomycin for urinary tract infections].
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
C Takada
Publications and source records attributed to C Takada.
Radiation therapy of primary malignant lymphoma of the brain.
Primary malignant lymphoma of the brain (PMLB) is uncommon. Between 1975 and 1982, the authors observed 11 patients with histologically confirmed PMLB. Mean survival after radiation therapy was 7 months with 5 patients surviving for more than 2 years. Multifocal lesions were seen in 9 patients and spontaneous regression was seen at computed tomography in 2 patients. Radiation doses in excess of 30 Gy controlled the primary tumor, but intracranial recurrences occurred even after whole brain irradiation to 40 Gy. Only one patient had a relapse outside the central nervous system, and none had clinical evidence of seeding to the spinal canal. The authors postulate that PMLB usually is a multifocal intracranial disease, and that whole brain irradiation of at least 30 to 40 Gy should be given to all patients with this disease.
Adult↗
The role of radiation therapy in adult T-cell leukemia.
Five patients with adult T-cell leukemia (ATL) were treated by irradiation. Of the five patients, four were irradiated only locally to enlarged lymph nodes or cutaneous lesions as a palliative therapy. The other patient was given a single dose of 10 Gy to the total body as a definitive treatment, followed by autologous bone marrow transplantation. All five patients were treated by combined chemotherapy before irradiation. Complete reduction of lymph node enlargement and cutaneous lesions was achieved with a dose of 20 to 30 Gy. Four patients died within three months after radiotherapy, but there was no recurrence in the radiation field while new lesions developed. One patient in whom cutaneous lesions developed again after nine months of remission was alive at 10 months after irradiation. These patients responded poorly to chemotherapy. Local lesions produced by ATL were sensitive to irradiation and could be controlled by moderate irradiation doses without severe side effects. Radiotherapy did not prolong survivals, but it should be considered as a palliative method in multimodal treatment for ATL.
Adult↗
Azelastine: its clinical application for radiation dermatitis.
A retrospective analysis was performed to investigate the radioprotective effects of azelastine against radiation dermatitis for patients with head and neck cancers. The effects of azelastine were studied in 19 patients with laryngeal cancers treated by irradiation. As controls, 29 patients with laryngeal cancers treated by irradiation without the administration of azelastine were studied. All patients were irradiated using 3 MV linac X-rays. Azelastine was administered orally twice a day. Moist desquamation was observed in four of 29 control patients whereas no such moist desquamation developed after the administration of azelastine. Two cases of moist desquamation that developed before the administration of azelastine regressed during irradiation in patients placed on azelastine. Radiotherapy was completed without interruption in all patients treated with azelastine. No severe side effects were observed. Azelastine, administered orally, was a safe drug and has the potential of improving skin tolerance in irradiation therapy.
Anti-Inflammatory Agents, Non-Steroidal↗
External radiation therapy of prostatic carcinoma and its relationship to hormonal therapy.
From 1980 to 1990, a total of 54 patients with prostatic carcinoma were treated with external radiation therapy at the Kumamoto National Hospital. Ten patients were classified as Stage B, 22 as Stage C, and another 22 as Stage D according to the American Urological Association Clinical Staging System. The 5-year survival for all 54 patients was 30%. The 5-year disease-specific survival was 67% for Stage B, 47% for Stage C, and 26% for Stage D. The 5-year survival was 43% for patients in whom radiation therapy was initiated immediately after the first diagnosis or with less than one year of hormonal therapy, while it was 0% for patients in whom radiation therapy was initiated after more than one year of hormonal therapy (p = 0.01). The cause of intercurrent death was acute myocardial infarction in four patients and acute cardiac failure in one. Four of these patients received hormonal therapy for more than one year. The incidence of radiation-induced proctitis was not severe. This study suggests that long-term hormonal therapy prior to radiation therapy worsens the prognosis of patients with prostatic carcinoma.
Aged↗